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Abstract
Background The aim of this study was to assess the safety and effectiveness of intravascular lithotripsy (IVL) in treating 
eccentric calcified coronary lesions.
Methods Between December 2015 and March 2019, 180 patients were enrolled in the Disrupt CAD I and CAD II studies 
across 19 sites in 10 countries. Patient-level data were pooled from these two studies (n = 180), within which 47 eccentric 
lesions (26%) and 133 concentric lesions were identified.
Results Clinical success, defined as residual stenosis < 50% after stenting and no in-hospital MACE, was similar between 
the eccentric and concentric cohorts (93.6% vs. 93.2%, p = 1.0). There were no perforations, abrupt closure, slow flow or 
no reflow events observed in either group, and there were low rates of flow-limiting dissections (Grade D–F: 0% eccentric, 
1.7% concentric; p = 0.54). Final acute gain and percent residual stenosis were similar between the two groups. Final residual 
stenosis of 8.6 ± 9.8% in eccentric and 10.0 ± 9.0% (p = 0.56) in concentric stenosis confirms the significant effect of IVL 
in calcified coronary lesions.
Conclusion In this first report from a pooled patient-level analysis of coronary IVL from the Disrupt CAD I and CAD II 
studies, IVL use was associated with consistent improvement in procedural and clinical outcomes in both eccentric and 
concentric calcified lesions.
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Introduction
Severe calcification of coronary stenoses still provides a 
major challenge for percutaneous coronary intervention 
(PCI). To avoid a sub-optimal clinical outcome, it is impor-
tant to achieve sufficient luminal gain during lesion prepa-
ration prior to stent implantation [1, 2]. Besides the risk of 
impaired stent expansion, severe coronary calcification may 
also lead to sub-optimal PCI outcomes by limiting lesion 
crossing, altering drug elution kinetics, and interfering with 
optimal stent expansion [3–7].
Intravascular lithotripsy (IVL) has been recently intro-
duced to modify calcified coronary plaques and is useful in 
overcoming some of the limitations of the more commonly 
used techniques, e.g., percutaneous transluminal coronary 
angioplasty (PTCA) with non-compliant (NC) balloons, cut-
ting-/scoring-balloons, and rotational atherectomy (RA). NC 
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balloon dilatation, even with high pressure, is often insuf-
ficient to apply the necessary force for disrupting calcifica-
tions. Due to the eccentricity of calcified lesions, balloon 
dilatation often results in disruption or dissection of healthy 
intima or fibrous plaques rather than modification of calci-
fied segments within the artery [8]. Cutting and scoring bal-
loons, though able to debulk the lesion more intensely than 
NC balloons suffer from the same limitation. Even rotational 
or orbital atherectomy (OA), the most effective techniques 
for modification of calcified plaques available prior to IVL, 
are limited due to guidewire bias, which may result in inho-
mogeneous ablation leaving significant areas of the calci-
fied plaques unmodified, particularly in eccentric lesions 
[9]. Additionally, periprocedural complications including 
slow-/no-flow, coronary perforation, periprocedural myo-
cardial infarction occur more frequently with atherectomy 
techniques as compared to balloon techniques [10, 11].
IVL catheters are equipped with emitters that deliver pul-
satile sonic pressure waves circumferentially to the vessel 
wall. IVL catheters are equipped with emitters along with 
the balloon that delivers pulsatile shockwaves to the sur-
rounding plaque after activation. An electrical discharge 
vaporizes the fluid within the balloon to generate a rapidly 
expanding bubble and collapses within a few microseconds 
afterward. Soft tissue transmits the pulsatile mechanical 
energy, while microfractures are induced in rigid calci-
fied structures and thus break up the calcified plaques. The 
treatment sequence takes 10 s, during which shockwaves 
are emitted at a frequency of 80 Hz. 2–4 sequences are per-
formed per vessel section. This provides the unique opportu-
nity to modify the calcified plaque homogenously and reach 
calcification even in deeper vessel layers. The aim of this 
study was to assess the safety and effectiveness of IVL in 
treating eccentric calcified coronary lesions.
Methods
Study design and population
Between December 2015 and March 2019, 180 patients were 
enrolled in the Disrupt CAD I and Disrupt CAD II stud-
ies across 19 sites in 10 countries. Disrupt CAD I (n = 60) 
was a pre-market, prospective, single-arm, multi-center 
study designed to evaluate the safety and performance of 
the Shockwave (Shockwave Medical Inc., Santa Clara, CA, 
USA) coronary intravascular lithotripsy (IVL) system in the 
treatment of calcified coronary lesions for the purpose of 
optimizing the placement of stents and reducing the ultimate 
residual stenosis [12].
Disrupt CAD II (n = 120) was a post-market study evalu-
ating the safety and performance of the coronary IVL sys-
tem following expansion to a broader patient population and 
additional physician users [13]. The inclusion and exclusion 
criteria for both studies were identical and included patients 
with significant native calcified coronary artery disease suit-
able for PCI. In both studies, patients were required to have 
a single target lesion requiring PCI with diameter steno-
sis ≥ 50%, lesion length ≤ 32 mm in native coronary arter-
ies, and severe calcification as determined by the operators, 
defined as calcification within the lesion on both sides of 
the vessel assessed by angiography. Primary endpoints of 
the Disrupt CAD I study were freedom from major adverse 
cardiac events (MACE) within 30 days of the procedure. 
MACE was defined as cardiac death, myocardial infarction 
or target vessel revascularization (TVR). IVL performance 
was defined as the ability of the IVL system to produce 
residual stenosis of < 50% after stenting without intra-hos-
pital MACE [12]. The primary endpoint of the Disrupt CAD 
II study was the frequency of in-hospital MACE [13].
The same independent angiographic core lab was uti-
lized for both studies and analyzed all procedural angio-
grams (Yale Cardiovascular Research Group, New Haven, 
CT, USA). The angiographic core lab defined an eccentric 
lesion as a stenotic lesion that had one of its luminal edges 
in the outer one-quarter of the apparent normal vessel lumen 
[14–16]. Concentric lesions were defined using the same 
criteria while involving both luminal edges. Whenever pos-
sible, multiple angiographic angles were used to confirm the 
lesion classification.
All patients gave written informed consent before enroll-
ment. The study was conducted in accordance with the Dec-
laration of Helsinki and applicable laws by all related gov-
ernmental bodies. Studies were registered at https ://www.
clini caltr ials.gov; their unique identifiers: NCT02650128 
and NCT03328949.
Study device
The coronary IVL system is a 6Fr compatible semi-com-
pliant balloon catheter, containing two electrically charged 
lithotripsy emitters, inserted over a rapid exchange 0.014″ 
guidewire [11–13]. Balloon catheters are available in several 
diameters (2.5–4.0 mm in steps of 0.5 mm) with a length of 
12 mm. The balloon is expanded to 4 atm by a fluid (50:50 
mixture of NaCl 0.9% and contrast media) optimized to 
transmit circumferential sonic pressure waves through soft 
vascular tissue. A small electrical discharge at the emitters 
vaporizes this fluid, thereby generating a rapidly expand-
ing and collapsing bubble within the balloon. The result-
ing mechanical energy (approximately 50 atm) selectively 
induces fractures in the calcium. The IVL system allows 
the manual application of individual therapy cycles, each 
comprising 10 pulses (one pulse per second) in series, with 
a maximum of eight cycles emitted by each catheter [13, 
17, 18].
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Study procedure
PCI was performed via 6Fr or larger femoral or radial 
access. The IVL catheter was inserted using a standard 
0.014″ guidewire. If passing the IVL device was initially 
unable to cross the target lesion, preparation with a small 
NC balloon (1.5 mm diameter), buddy wire-technique 
or guidewire extension was allowed per protocol. Lith-
otripsy-balloon diameter was selected 1:1 according to 
the angiographically estimated reference lumen diameter. 
After positioning, the balloon was inflated to 4 atm to 
achieve proper contact with the vessel wall and one cycle 
was delivered; the balloon was inflated to 6 atm subse-
quently. Treatment cycles were repeated as necessary to 
cover the whole lesion. If the maximum of eight cycles 
(80 pulses) had been delivered without sufficient lesion 
preparation, the use of additional IVL catheters with the 
same or larger diameters was allowed per protocol. Stent 
implantation and post-dilatation were performed accord-
ing to the standard of care in each institution. Post-proce-
dure medication and selection of dual antiplatelet therapy 
were at the discretion of the operator. Clinical follow-up 
was conducted 30 days post-procedure by standardized 
telephone interview.
Statistical analysis
Patient baseline characteristics and procedural data were 
analyzed and represented using frequency, mean, SD, and 
median. In comparing two groups, the t test or Wilcoxon 
sum test was utilized for continuous variables and Fish-
er’s exact test for dichotomous variables. All statistical 
tests were two-sided, with p values < 0.05 considered sta-
tistically significant. Statistical analyses were performed 
using SAS (SAS Institute, Cary, NC, USA), version 9.4.
Results
Patient data
Patient-level data were pooled from Disrupt CAD I and Dis-
rupt CAD II study with eccentric lesions identified in 47 
patients and concentric lesions in 133 patients. Mean patient 
age was 72.1 ± 9.7 years. There were no significant differ-
ences between patients with eccentric or concentric lesions 
regarding baseline characteristics (Table 1). There was a 
trend towards higher frequencies of previous myocardial 
infarction (40.4% vs. 27.1%; p = 0.10), arrhythmias (31.9% 
vs. 18%; p = 0.06) and renal insufficiency (14.9% vs. 6.8%; 
p = 0.13) in patients with eccentric stenoses as compared to 
patients with concentric stenoses.
Lesion characteristics
Target lesions were located in the left anterior descending 
artery in 57.2%, in the right coronary artery in 29.5%, in the 
circumflex artery in 12.2%, and in the protected left main in 
1.1%. There were no significant differences between groups 
regarding the lesion location. However, patients with eccen-
tric lesions demonstrated significantly larger reference ves-
sel diameter (RVD, 3.2 ± 0.6 mm vs. 3.0 ± 0.5 mm; p = 0.04 
and significantly shorter lesion length (16.7 ± 7.0 mm vs. 
20.9 ± 10.7 mm; p = 0.01) as compared to patients with con-
centric lesions. For detailed lesion characteristics see also 
Table 2.
Procedural characteristics
Pre-dilatation was performed in 40% of patients and post-dil-
atation in 81.7%. Mean procedure time was 76.5 ± 37.0 min, 
mean fluoroscopy time 22.7 ± 15.9 min, and mean contrast 
load 207.3 ± 87.5 ml. The number of IVL treatment cycles 
delivered was heavily left-skewed, with a median of 68.5 
[40, 80] IVL pulses delivered, translating to 3.5 [2.5, 5.8] 
Table 1  Baseline characteristics
Values are mean ± standard deviation or n (%)
a MI myocardial infarction
Overall (n = 180) Eccentric (n = 47) Concentric (n = 133) p value
Age 72.1 ± 9.7 73.0 ± 10.1 71.8 ± 9.6 0.35
Male 142 (78.9) 38 (80.9) 104 (78.2) 0.84
Diabetes 56 (31.1) 17 (36.2) 39 (29.3) 0.49
Hypertension 144 (80.0) 39 (83.0) 105 (78.9) 0.70
Hyperlipidemia 134 (74.4) 34 (72.3) 100 (75.2) 0.85
Renal Insufficiency 16 (8.9) 7 (14.9) 9 (6.8) 0.13
MIa 55 (30.6) 19 (40.4) 36 (27.1) 0.10
Arrhythmia 39 (21.7) 15 (31.9) 24 (18.0) 0.06
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IVL pulses/mm of lesion length; this was consistent between 
patients with eccentric and concentric lesions. Intravascular 
imaging using optical coherence tomography was performed 
in 78 patients (43%). No procedural characteristics differed 
significantly between groups. See also Table 3.
Outcome
Clinical success, defined as final post-stent residual ste-
nosis < 50% after stenting with no in-hospital MACE, was 
achieved in 93.3% of patients (Eccentric: 93.6% vs. con-
centric 93.2%; p = 0.80). Angiographic success, defined as 
success in facilitating stent delivery with < 50% residual 
stenosis and without major angiographic complications 
(severe dissection impairing flow [type D–F], perforation, 
abrupt closure, persistent slow flow, or no reflow), was 
achieved in 98.9% of patients (Eccentric: 100% vs. concen-
tric 98.5%; p = 0.97). An exploratory goal of < 30% residual 
stenosis was achieved with high frequency in both groups 
(Eccentric: 97.9% vs. concentric 97.0%; p = 0.84). Residual 
percent diameter stenosis (Eccentric: 61.7 ± 14.1% vs. con-
centric: 63.1 ± 12.5%; p = 0.44) and acute gain (Eccentric: 
1.8 ± 0.5 mm vs. concentric: 1.7 ± 0.5 mm; p = 0.47) were 
similar between groups. Representative angiographic and 
optical coherence tomography images from eccentric and 
concentric lesions are shown in Fig. 1.
Table 2  Lesion characteristics
Values are mean ± standard deviation or n (%). Severe calcification was confirmed by angiography when 
radiopacity was noted without cardiac motion prior to contrast injection
a LM left main
b LAD left anterior descending artery
c Cx circumflex artery
d RCA right coronary artery
e RVD reference vessel diameter
f MLD minimum lumen diameter
g DS diameter stenosis
Overall (n = 180) Eccentric (n = 47) Concentric (n = 133) p value
Target vessel
 Protected  LMa 2 (1.1) 2 (4.3) 0 (0.0) 0.10
 LADb 103 (57.2) 23 (48.9) 80 (60.2)
 Cxc 22 (12.2) 3 (6.4) 19 (14.3)
 RCA d 53 (29.4) 19 (40.4) 34 (25.6)
RVDe (mm) 3.0 ± 0.5 3.2 ± 0.6 3.0 ± 0.5 0.03
MLDf (mm) 1.1 ± 0.4 1.2 ± 0.5 1.1 ± 0.4 0.11
DSg (%) 62.7 ± 12.9 61.7 ± 14.1 63.1 ± 12.5 0.44
Lesion length (mm) 19.8 ± 10.0 16.7 ± 7.0 20.9 ± 10.7 0.04
Calcified length (mm) 24.6 ± 12.5 24.2 ± 15.7 24.8 ± 11.3 0.18
Severe calcification 161 (89.4) 41 (87.2) 120 (90.2) 0.77
Table 3  Procedural 
characteristics
Values are mean ± standard deviation or median [Q1, Q3] or n (%)
a IVL intravascular lithotripsy
Overall (n = 180) Eccentric (n = 47) Concentric (n = 133) p value
Procedure time (min) 76.5 ± 37.0 74.6 ± 40.1 77.2 ± 36.0 0.46
Fluoroscopy time (min) 22.7 ± 15.9 19.8 ± 13.5 23.8 ± 16.6 0.35
Contrast volume (ml) 207.3 ± 87.5 191.5 ± 87.7 212.8 ± 87.0 0.07
IVLa catheters (n) 1.5 ± 0.9 1.3 ± 0.6 1.5 ± 0.9 0.22
IVLa pulses (n) 68.5 [40, 80] 60 [50, 80] 70 [40, 80] 0.79
Pulses/mm lesion length 3.5 [2.5, 5.8] 3.7 [2.9, 6.5] 3.4 [2.3, 5.1] 0.13
Max  IVLa inflation pressure 5.8 ± 0.8 6.0 ± 0.7 5.8 ± 0.8 0.15
Number of stents (n) 1.4 ± 0.7 1.3 ± 0.5 1.4 ± 0.7 0.12
Pre-dilatation 72 (40.0) 20 (42.6) 52 (39.1) 0.81
Post-dilatation 147 (81.7) 36 (76.6) 111 (83.5) 0.41
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After IVL, no perforations, abrupt closure, slow-flow or 
no-reflow events were observed in either group, and low rate 
of flow-limiting dissections (Grade D–F: Eccentric 0% vs. 
concentric 1.7%, p = 0.54) occurred. All dissections were 
resolved with stent delivery.
During in-hospital follow-up, there were two cases 
(4.3%) of non-Q-wave myocardial infarction in patients with 
eccentric lesions and eight cases (6.0%) in patients with con-
centric lesions (p = 0.93). Neither group experienced cardiac 
death or target vessel revascularization during in-hospital 
follow-up.
The 30-day MACE rate was 8.7% in patients with 
eccentric lesions and 6.0% in patients with concentric 
lesions (p = 0.80). No new observations of non-Q-wave 
Fig. 1  IVL in eccentric and 
concentric coronary lesions. 
Representative angiography and 
optical coherence tomography 
images from cases involving an 
a eccentric lesion and b concen-
tric lesion. Fractured calcium 
is visible within the intimal 
and medial vessel layers for 
both lesions. In each example, 
increased lumen area is notable 
post IVL treatment and again 
post stent
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myocardial infarction were observed following hospital 
discharge. There was one cardiac death in the group with 
eccentric lesions. The cardiac death occurred in a 70-year-
old who originally presented with pre-syncope and died 
suddenly 14 days after treatment of a 95% lesion in the 
distal right coronary artery. The inclusion of this patient 
was a protocol deviation, as the patient met defined angi-
ographic exclusion criterion (second lesion with ≥ 50% 
stenosis in the same target vessel) due to occluded pos-
terior descending coronary artery and reference vessel 
diameter > 4.0 mm (quantitative coronary angiography: 
4.57 mm) [15]. There were no significant differences in 
the frequency of 30-day MACE when comparing patients 
with eccentric and concentric lesions. For detailed out-
come data see also Tables 4, 5, 6 and 7.
Discussion
The main findings of this pooled patient-level analysis are 
that IVL treatment of eccentric coronary lesions is asso-
ciated with consistent outcomes including high procedure 
success and low vascular complications and that there are 
no significant differences regarding procedural and clinical 
outcome when comparing IVL treatment of eccentric with 
concentric lesions.
IVL provides a unique therapy to modify calcified coro-
nary plaques even in deeper vessel layers [12, 13]. IVL 
mechanical pressure waves are transduced through the 
soft tissue of the vessel wall. Rigid calcifications cannot 
transduce this mechanical energy, so the energy selectively 
fractures calcified plaque. All other debulking techniques 
Table 4  Performance outcomes
Values are mean ± standard deviation or n (%)
a MSD minimum stent diameter
Overall (n = 180) Eccentric (n = 47) Concentric (n = 133) p value
Clinical success 168 (93.3) 44 (93.6) 124 (93.2) 1.0
Angiographic success 178 (98.9) 47 (100.0) 131 (98.5) 1.0
Stent delivery 180 (100.0) 47 (100.0) 133 (100.0)
Final in-stent angiographic outcomes
 MSDa (mm) 2.8 ± 0.5 3.0 ± 0.5 2.7 ± 0.5 0.004
 Residual stenosis (%) 9.7 ± 9.2 8.6 ± 9.8 10.0 ± 9.0 0.56
Acute gain (mm) 1.7 ± 0.5 1.8 ± 0.5 1.7 ± 0.5 0.47
Residual stenosis < 50% 180 (100.0) 47 (100.0) 133 (100.0)
Residual stenosis < 30% 175 (97.2) 46 (97.9) 129 (97.0) 0.84
Table 5  Angiographic 
complications—Post-IVL
Values are n (%)
Overall (n = 161) Eccentric (n = 44) Concentric 
(n = 117)
p value
Dissections, type D–F 2 (1.2) 0 (0.0) 2 (1.7) 0.54
Perforation 0 (0.0) 0 (0.0) 0 (0.0)
Abrupt closure 0 (0.0) 0 (0.0) 0 (0.0)
Slow flow 0 (0.0) 0 (0.0) 0 (0.0)
No reflow 0 (0.0) 0 (0.0) 0 (0.0)
Table 6  Angiographic 
complications—Final
Values are n (%)




 D–F 0 (0.0) 0 (0.0) 0 (0.0)
 Perforation 0 (0.0) 0 (0.0) 0 (0.0)
 Abrupt closure 0 (0.0) 0 (0.0) 0 (0.0)
 Slow flow 0 (0.0) 0 (0.0) 0 (0.0)
 No reflow 0 (0.0) 0 (0.0) 0 (0.0)
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(Cutting-/Scoring-Balloon, atherectomy techniques) may 
suffer from guidewire bias leading to inhomogeneous 
plaque modification [9, 19–21]. OA and RA modify cal-
cified plaque by generating a relatively smooth, circular 
channel, strictly following the guidewire [19, 21–24]. This 
facilitates balloon or stent delivery, although the gain in 
the cross-sectional area is modest [24]. Nevertheless, it 
must be kept in mind, that this atherectomy “tunnel” may 
not be located centrally in the coronary artery which can 
result in asymmetric stent expansion and undesirable clini-
cal outcomes. Furthermore, in regions with tortuosity and 
eccentric lesions, there is a significant risk of coronary 
perforation with OA or RA [25] and damage to healthy 
portions of the vessel wall. Eccentric coronary calcifi-
cations are particularly difficult to modify by OA or RA 
atherectomy due to the guidewire being displaced away 
from the target lesion. In comparison, the IVL balloon 
inflated to 4 atm is in contact with all parts of the sur-
rounding vessel and therefore has no guidewire bias. This 
provides the possibility for homogeneous plaque modi-
fication, in both the intima and the media, especially in 
eccentric coronary plaques that are usually associated 
with suboptimal outcomes after PCI [26, 27]. Patient age 
has continuously increased over the past years resulting in 
higher calcium burden of coronary plaques as well as more 
complex coronary stenoses, such as eccentric calcified cor-
onary lesions. The increasing frequency of these complex 
lesions is associated with an impaired clinical outcome 
[28]. Therefore, promising treatment options for eccen-
tric calcified lesions, such as IVL, need to be evaluated 
and established in clinical routine. IVL has demonstrated 
effective treatment of calcifications located in deeper ves-
sel layers [13, 29]. Circumferential plaque modification 
results in increased vessel compliance, demonstrated by 
increasing vessel diameter during constant balloon pres-
sure [18]. As a result, IVL facilitates full, symmetrical 
stent expansion [13].
As the utilization of IVL has increased, there has been 
much discussion as to which clinical cases the technology 
is best suited for. In this first comparison between eccen-
tric and concentric lesions, as defined angiographically, it 
is instructive to observe high procedural success rates with 
IVL regardless of lesion type. Angiographic success was 
achieved in 100% of eccentric lesions and 98.5% of con-
centric lesions, which emphasizes the effectiveness of IVL 
in treating a wide range of stenoses. This clinical success 
was achieved using a similar number of pulses/mm lesions 
among the two groups in this study. Per protocol, the goal 
was to deliver lithotripsy until < 50% residual stenosis was 
achieved, but ending therapy was at physician’s discretion 
and there were no limitations to the absolute number of 
pulses delivered. Regardless of the variability in the strat-
egy of pulse delivery, the number of pulses delivered, and 
the pulses/mm lesion was similar between eccentric and 
concentric lesions. Accordingly, this analysis demonstrates 
no limitations in the efficiency or effectiveness of IVL 
treatment in eccentric lesions. Based on the results of this 
study, IVL should be considered as a valuable treatment 
option in both eccentric and concentric calcified lesions. 
This seems to be even more important when considering 
that rotational or orbital atherectomy, the most effective 
techniques prior to IVL, is limited due to guidewire bias, 
which may result in inhomogeneous ablation leaving sig-
nificantly unmodified areas in eccentric lesions. Moreo-
ver, it may be suited to make safe and effective plaque 
modulation in calcified coronary stenoses available for 
a wider patient collective than it is at the moment since 
Table 7  MACE
Values are n (%)
a MI myocardial infarction
b TVR target vessel revascularization
*One subject with two events; one subject withdrew prior to the 30-day end-point
Overall (n = 180) Eccentric (n = 47) Concentric 
(n = 133)
p value
In-hospital 10 (5.6) 2 (4.3) 8 (6.0) 0.93
Cardiac death 0 (0.0) 0 (0.0) 0 (0.0)
Non-Q-wave  MIa 10 (5.6) 2 (4.3) 8 (6.0)
Q-wave  MIa 0 (0.0) 0 (0.0) 0 (0.0)
TVRb 0 (0.0) 0 (0.0) 0 (0.0)
30-day* 12 (6.7) 4 (8.7) 8 (6.0) 0.80
Cardiac death 1 (0.6) 1 (2.2) 0 (0.0)
Non-Q-wave  MIa 10 (5.6) 2 (4.3) 8 (6.0)
Q-wave  MIa 1 (0.6) 1 (2.2) 0 (0.0)
TVRb 1 (0.6) 1 (2.2) 0 (0.0)
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atherectomy techniques are only used in a small part of 
patients in need due to their technical complexity [30, 31].
According to our results, Mattesini et al. reported similar 
results for IVL treatment of eccentric (Calcium arc > 180°) 
and concentric calcified stenosis (Calcium arc ≤ 180°) when 
comparing the acute results using intravascular imaging by 
optical coherence tomography in a prospective registry 
including 28 patients [32]. There were no significant differ-
ences regarding in-stent minimum lumen diameter, in-stent 
minimal lumen area, and the acute gain when comparing 
eccentric and concentric calcified stenoses. If this really 
translates into lower adverse event rates and better clinical 
outcome needs to be evaluated in future clinical trials.
Limitations
Our study has a number of limitations. First, this is a retro-
spective pooled analysis from two different studies that were 
designed for evaluating the safety and procedural success of 
IVL. Nevertheless, the inclusion and exclusion criteria of 
both studies were identical and data analysis was performed 
by the same independent core lab. Patient numbers were 
quite small with 180 patients being included in the aggre-
gated studies. Nonetheless, this study includes the largest 
number of patients with coronary IVL treatment performed 
so far.
A further limitation is the angiographic endpoint of clini-
cal success, defined as residual diameter stenosis of less than 
50% after IVL and stenting, which is quite conservative. The 
endpoint was chosen as equivalent to the ORBIT II study 
which was used as a primary comparator for the Disrupt 
CAD I study [33]. Nonetheless, the final residual stenosis of 
8.6 ± 9.8% in eccentric and 10.0 ± 9.0% (p = 0.56) in concen-
tric stenosis confirms the significant effect of IVL on these 
lesions. Additionally, given the angiographic limitations in 
determining the exact arc of calcium within the lesions, fur-
ther insights from planned OCT and IVUS analyses from the 
Disrupt CAD clinical program will add additional valuable 
insights.
Future clinical trials should focus on comparing IVL and 
other debulking techniques for the treatment of calcified 
coronary lesions to evaluate the technique in comparison to 
the current standards of care. No according data have been 
published so far.
Conclusion
In this first report from a pooled patient-level analysis of 
coronary IVL from the Disrupt CAD I and CAD II studies, 
IVL use was associated with high procedural success and 
consistent clinical outcomes in both eccentric and concentric 
calcified lesions.
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